PPARγ activators for the treatment of cardiopulmonary remodeling and failure

Prof. Dr. Georg Hansmann
Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Germany

Pulmonary vascular disease is a progressive, angio-obliterative disease leading to increased pulmonary vascular resistance, pulmonary arterial hypertension, heart failure, and death in ~50%/5 years. RV dysfunction (RVD) is also common in (left) heart failure with preserved ejection fraction (HFpEF) and AF. The “dogma” that RV dysfunction is exclusively a direct consequence of PA pressure elevation in PAH, and that targeted therapy does not need to directly address RV dysfunction in either PAH or HFpEF in left heart diseases, has recently been challenged. Prof. Hansmanns translational research aims to develop reverse-remodeling strategies for the treatment of pulmonary vascular disease, pulmonary hypertension and heart failure through preclinical and human tissue studies, leading to early, tailored clinical pilot studies.

Wednesday, 20.01.2016
12:00 – 13:00h
Bibliothek at DHZB
Augustenburger Platz 1, Berlin